Galapagos begins Phase I study of cachexia drug candidate
This article was originally published in Scrip
Executive Summary
Galapagos has started a Phase I, "proof-of-mechanism" study for its selective androgen receptor modulator (SARM) GLPG0492 for cachexia, a condition characterised by loss of weight and muscle mass. The product could also have development potential in other indications such as Duchenne muscular dystrophy (DMD), the company said.